0001181431-11-030133.txt : 20110516
0001181431-11-030133.hdr.sgml : 20110516
20110516173439
ACCESSION NUMBER: 0001181431-11-030133
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110512
FILED AS OF DATE: 20110516
DATE AS OF CHANGE: 20110516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cole Douglas G.
CENTRAL INDEX KEY: 0001486373
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34655
FILM NUMBER: 11848970
MAIL ADDRESS:
STREET 1: AVEO PHARMACEUTICALS, INC.
STREET 2: 75 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001325879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 SIDNEY STREET
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6172995000
MAIL ADDRESS:
STREET 1: 75 SIDNEY STREET
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
rrd311872.xml
COLE FORM 4
X0303
4
2011-05-12
0
0001325879
AVEO PHARMACEUTICALS INC
AVEO
0001486373
Cole Douglas G.
C/O AVEO PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2011-05-12
4
S
0
919
17.3033
D
31540
I
by AGTC Advisors Fund, L.P.
Common Stock
2011-05-12
4
S
0
15200
17.3033
D
521815
I
by Applied Genomic Technology Capital Fund, L.P.
Common Stock
2011-05-13
4
S
0
4639
17.7517
D
26901
I
by AGTC Advisors Fund, L.P.
Common Stock
2011-05-13
4
S
0
76750
17.7518
D
445065
I
by Applied Genomic Technology Capital Fund, L.P.
Common Stock
2011-05-16
4
S
0
2992
17.9772
D
23909
I
by AGTC Advisors Fund, L.P.
Common Stock
2011-05-16
4
S
0
49500
17.9773
D
395565
I
by Applied Genomic Technology Capital Fund, L.P.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by AGTC Advisors Fund, L.P. on November 9, 2010.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.30 to $17.32, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
Held by AGTC Advisors Fund, L.P.; NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship Inc."). Noubar B. Ayefan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and may be deemed to have beneficial ownership with respect to all shares held by AGTC Advisors Fund, L.P. The reporting person disclaims beneficial owenrship over shares held by AGTC Advisors Fund, L.P.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Applied Genomic Technology Capital Fund, L.P. on November 9, 2010
Held by Applied Genomic Technology Capital Fund, L.P.; NewcoGen Group, Inc. ("NewcoGen") is the general partner of AGTC Partners, L.P., which is the general partner of Applied Genomic Technology Capital Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc.("Flagship"). Noubar B. Afeyan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and they may be deemed to have beneficial ownership with respect to all shares held by Applied Genomic Technology Capital Fund, L.P. The reporting person disclaims beneficial ownership over shares held by Applied Genomic Technology Capital Fund, L.P.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.30 to $18.10, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.68 to $18.52, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
/s/ Joseph D. Vittiglio, Esq, attorney-in-fact
2011-05-16